Premium
Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF , KRAS , HRAS , NRAS, GNA11, and GNA14 mutations
Author(s) -
Pereira Thaís dos Santos Fontes,
Amorim Larissa Stefhanne Damasceno,
Pereira Núbia Braga,
Vitório Jéssica Gardone,
DuarteAndrade Filipe Fideles,
Guimarães Letícia Martins,
Diniz Marina Gonçalves,
Gomes Carolina Cavaliéri,
Gomez Ricardo Santiago
Publication year - 2019
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12922
Subject(s) - hras , neuroblastoma ras viral oncogene homolog , mapk/erk pathway , kras , gnaq , cancer research , sanger sequencing , medicine , biology , signal transduction , mutation , gene , genetics
Background Pyogenic granuloma (PG) is a benign nodular lesion with a prominent vascular component which may affect different sites. Recently, BRAF , KRAS , HRAS , NRAS, GNA11, and GNA14 mutations were reported on PGs of the skin. The present study assessed the role of the MAPK/ERK pathway in oral PG pathogenesis. Methods Mutations in hotspot regions of genes involved in the MAPK/ERK pathway activation were investigated by Sanger sequencing. The expression of phospho‐ERK1/2 was evaluated by immunohistochemistry. Results Oral PGs did not show mutations in the sequenced regions of the genes BRAF , KRAS , HRAS , NRAS, GNA11, or GNA14 . Our results also showed activation of the MAPK/ERK pathway demonstrated by phospho‐ERK1/2 immunohistochemical positivity. Conclusions Although oral PG shows MAPK/ERK pathway activation, the driver molecular event remains to be elucidated.